Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
175
resultados
Última actualización
07/06/2025 [07:45:00]
Resultados 25 a 50 de 175
Resumen de: WO2024018364A1
Provided is an enveloped virus-like particle (eVLP) comprising a substantially full-length recombinant SARS-CoV-2 spike (S) protein. The eVLP may further comprise an additional recombinant SARS-CoV-2 S protein having a different sequence, another recombinant viral antigen, or a recombinant non-viral protein. The eVLP is derived from an animal cell, such as a CHO cell, expressing the recombinant SARS-CoV-2 spike protein. Also provided are methods of producing such eVLPs, compositions including such eVLPs, and methods and uses for the induction of an immune response against a SARS-CoV-2 spike protein and/or prevention of COVID-19 or SARS-CoV-2 infection, employing such eVLPs.
Resumen de: EP4560010A1
The present invention relates to a COVID-19 infection model using alveolar organoids. Respiratory virus-infected alveolar organoids produced according to the present invention are expected to be usefully used in preclinical or clinical drug screening and the like for the development of therapeutic agents for SARS-CoV-2 infection.
Resumen de: EP4560021A1
The present invention relates to an RNA encoding the S protein of SARS-COV-2, a vaccine comprising the RNA, and uses thereof. The present invention also relates to a universal polynucleotide molecule comprising a 5'-UTR and/or a 3'- UTR, and a nucleic acid sequence encoding a protein and/or polypeptide of interest, and optionally comprising a polyA.
Resumen de: MA61946B1
The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Resumen de: ZA202407723B
The present disclosure provides a method for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection on the basis of receptor binding, including: subjecting crosslinked agarose as a matrix to surface carboxyl modification to obtain a magnetic agarose microsphere, and covalently coupling the magnetic agarose microsphere with a receptor protein to obtain a receptor protein-coupled magnetic agarose microsphere; allowing the receptor protein covalently binding to a surface of the receptor protein-coupled magnetic agarose microsphere to recognize and bind to a receptor-binding domain (RBD) of an outer membrane protein S of a SARS-CoV-2 sample, which simulates a binding process of the SARS-CoV-2 to a host cell to capture the SARS-CoV-2; subjecting the magnetic microsphere to washing, purification, and elution successively to obtain the SARS-CoV-2 with a cell binding ability; and detecting by an immunobinding-fluorescence quantitative polymerase chain reaction (PCR) combination, and evaluating infectivity and transmissibility of the SARS-CoV-2. The method is suitable for evaluating the replication and transmission of the SARS-CoV-2 in a patient infected with the SARS-CoV-2 during a treatment process and the infectivity of the SARS-CoV-2 carried by a patient with relapse symptoms after recovery.
Resumen de: WO2025104281A1
The present invention belongs to the field of compounds for use in therapeutic treatment, and more particularly hop derived compounds for use in the treatment of diseases caused by coronaviruses. The main field of application is human health, through the development of new active beta-acid-type antivirals against SARS-CoV-2. The present invention relates to hop derived compounds according to the invention for use in the treatment of diseases caused by a virus chosen from coronaviruses belonging to the Coronaviridae family.
Resumen de: WO2025106754A1
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
Resumen de: WO2025106738A1
Disclosed herein are compositions comprising protein antigens and RNA encoding the same (e.g., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can result in an improved immune response as compared to current SARS-COV-2 vaccines.
Resumen de: US2025164510A1
A method of assessing a COVID-19 infection in a person, the method comprising analysing the concentration or levels of one or more biomarkers in a biological sample from a person, wherein the one or more biomarkers comprises γ′ fibrinogen, and wherein concentration or levels of γ′ fibrinogen are elevated in a biological sample from a person infected with COVID-19 and can be used for predicting COVID-19 disease severity and/or for making a prognosis of severe COVID-19 disease in a person infected with COVID-19.
Resumen de: US2025161518A1
The invention concerns a microwave disinfection device (2) configured to destroy/inactivate the SARS-COV-2 and H1N1 viruses and comprising a microwave irradiation section (22) configured to: irradiate microwave signals that have an incident electric field amplitude not higher than 6 V/m and frequencies that are included in the 8-10 GHz band and are spaced from each other by a step comprised between 10 MHZ and 100 MHz; irradiate the microwave signals at each individual frequency for a time interval comprised between 50 ms and 1 s; and irradiate the microwave signals with duty cycles comprised between 5% and 50%.
Resumen de: US2025161433A1
The present invention relates to universal sarbecovirus vaccines that specifically express an interferon. This live universal sarbecovirus vaccine elicits mucosal immunity and heterotypic immunity against various sarbecoviruses, including SARS-CoV-1, SARS-CoV-2, and its variants. Interferon directly encoded from the genome of the live universal sarbecovirus overrides the virus-induced “delayed type-I interferon”, resulting in enhancement of mucosal T cell responses. The present invention further relates to uses of the vaccines for the preparation of pharmaceutical compositions, methods of treating or preventing viral infections, and kits comprising the vaccines.
Resumen de: US2025163107A1
Provided are a fusion protein and use thereof. Provided is a fusion protein, comprising a trimerization block and an immunogenic block which are connected by a linker, wherein the trimerization block comprises one or more of repeat units set forth in SEQ ID NO. 1; the immunogenic block is an immunogenic protein of a pathogen, for example, being selected from a coronavirus RBD block, an HIV membrane protein or an influenza virus hemagglutinin protein, and immunogenic fragments thereof. Compared with an immunogen monomer, the trimer can generate a higher neutralizing antibody level, does not induce a strong antibody against the trimerization block in a human body, and can promote the immune response of the organism to be focused on the immunogenic block.
Resumen de: US2025163026A1
The present invention is concerned with novel deuterium-enriched compounds of the general chemical structural formula I., and pharmaceutically acceptable salts, compositions, and methods of use thereof,wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25 are independently D (deuterium), H (hydrogen). The compounds of general chemical formula I are novel deuterium-enriched analogs of the SARS-CoV-2 main protease (MPro) inhibitor Nirmatrelvir for the treatment of COVID-19 and related diseases caused by various coronaviruses and their variants.
Resumen de: US2025161308A1
The present disclosure relates to a method of treating long-term sequelae of infection with SARS-CoV-2, also known as long COVID. More particularly, it discloses the method of treating long COVID, the method comprising administering to a patient in need thereof a therapeutically effective amount of a HGF/MET positive modulating agent.
Resumen de: US2025161262A1
Pharmaceutical compositions and methods for preventing, treating, relieving, or ameliorating symptoms of coronavirus infection, including COVID-19 and variants thereof, including treating or preventing severe illness from corona vims infection, comprising the administration of IMPDH inhibitors and/or restricted diets of guanosine-containing nucleosides or nucleotides.
Resumen de: US2025161431A1
This composition of this invention is comprised of live attenuated SARS-CoV-2 constructs as vaccines or research tools. Described herein is a highly attenuated SARS-CoV-2 with deleted accessory proteins and modified transcriptional regulator sequences (TRS) that can serve as a live-attenuated vaccine platform and a BSL-2 experimental system. Certain embodiments are directed to a live attenuated SARS-CoV-2 having a modified transcriptional regulatory sequence (TRS) and a deletion of one or more open reading frames selected from ORF3a, ORF3, ORF6, ORF7, and/or ORFS.
Resumen de: AU2023375894A1
The disclosure provides, in various embodiments, polypeptides (e.g, antibodies and antigen binding fragments thereof) that specifically bind to receptor binding domains (RBDs) of betacoronavirus Spike glycoproteins, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoproteins. The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating viral infections (e.g., COVID-19).
Resumen de: WO2025106425A1
The disclosure provides a composition comprising a nucleic acid encoding a human alpha coronavirus (HCoV) receptor binding domain (RBD) peptide and a severe acute respiratory syndrome coronavirus 2 (SCoV2) RBD peptide.
Resumen de: WO2025106792A1
Provided herein is a stable mutant coronavirus spike protein stem domain in a prefusion conformation comprising: an S2 subunit only, that has been modified to comprise; at least one additional intra-monomeric disulfide bond that stabilizes the S2 subunit; and 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the mutant coronavirus pre-fusion, S2-only spike protein maintains the prefusion conformation. Coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, existing variants, or an emerging variant thereof.
Resumen de: EP4556021A1
The present disclosure provides a composition for inducing or maintaining an immune response against SARS-CoV-2 virus.
Resumen de: PH12022552054A1
The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.
Resumen de: EP4556490A1
The present disclosure relates to a neutralizing antibody against SARS-coronavirus 2 (SARS-CoV2) or a variant virus thereof, or an antigen-binding fragment thereof. Since the neutralizing antibody of the present disclosure has inhibitory effect against SARS-coronavirus 2 and variants thereof (e.g., Delta variant, Omicron variant, etc.), it can be usefully used for prevention or treatment of infection by SARS-coronavirus 2 or variants thereof.
Resumen de: EP4556004A1
The present invention belongs to the field of compounds for use in therapeutic treatment, and more particularly hop derived compounds for use in the treatment of diseases caused by coronaviruses.The main field of application is human health, through the development of new active beta-acid-type antivirals against SARS-CoV-2The present invention relates to hop derived compounds according to the invention for use in the treatment of diseases caused by a virus chosen from coronaviruses belonging to the Coronaviridae family.
Resumen de: US12308098B1
A personal and reusable infection status passport device is disclosed that is configured to test for Covid-19 and infectious disease using photo and color analysis. The personal and reusable infection status passport device provides a supervisory testing unit/system to ensure testing is current and accurate. The quick and ease of use will allow for frequent testing so the individual will know their status without spending hours at a clinic or large sums of money on many single use tests. The test units are easier to produce and use with the main device. The device is capable of using a time stamp to ensure the test is current. The included processor and software will create a “status passport” system that will allow users to share their Covid-19 status as needed to comply with state, federal, local, and OSHA.
Nº publicación: AU2023353862A1 15/05/2025
Solicitante:
CAPRICOR INC
CAPRICOR, INC
Resumen de: AU2023353862A1
The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants and other respiratory viruses that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein, engineered nucleocapsid protein, engineered hemagglutinin protein, and/or engineered respiratory syncytial virus prefusion or fusion (RSV F) protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display, nucleocapsid-display, hemagglutinin-display, and/or RSV F-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple respiratory viruses and variants.
BOPI
Sede Electrónica
